Brokerages Set REGENXBIO Inc. (NASDAQ:RGNX) Price Target at $35.27

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have been given an average rating of “Moderate Buy” by the twelve analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $35.27.

Several research analysts have issued reports on the company. HC Wainwright cut their price objective on REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Raymond James reissued an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 target price on shares of REGENXBIO in a report on Wednesday, December 11th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a research report on Friday, November 15th.

REGENXBIO Trading Down 8.3 %

Shares of RGNX stock opened at $7.77 on Thursday. REGENXBIO has a 12-month low of $7.54 and a 12-month high of $28.80. The company has a market cap of $384.96 million, a price-to-earnings ratio of -1.54 and a beta of 1.24. The stock has a 50 day simple moving average of $9.70 and a 200-day simple moving average of $11.29.

Insider Transactions at REGENXBIO

In other news, Director Argeris N. Karabelas sold 10,000 shares of REGENXBIO stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now directly owns 11,286 shares in the company, valued at $114,101.46. The trade was a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 13.13% of the company’s stock.

Institutional Trading of REGENXBIO

Hedge funds have recently bought and sold shares of the company. FMR LLC lifted its stake in shares of REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares during the period. nVerses Capital LLC increased its stake in REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 2,200 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in REGENXBIO by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after buying an additional 3,720 shares during the period. Diversified Trust Co acquired a new stake in REGENXBIO in the 2nd quarter worth about $121,000. Finally, Arizona State Retirement System boosted its stake in REGENXBIO by 20.6% in the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock worth $137,000 after buying an additional 1,997 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.